The UMKC Health Sciences District (HSD) Research Council is focused on addressing substance use disorders (SUD) and the national opioid epidemic. Our goal is to foster collaboration between UMKC Health Sciences District members so that focused cross-disciplinary approaches to these can be developed.

We invite you to review the following list of funding opportunities that may be of interest to opioid researchers.  To add other opportunities to this list, please email us: Info@UMKCHealthSciencesDistrict.org

This information is abstracted for brevity; please refer to the sponsor’s website for complete information.

Funding Opportunities (as of June 27, 2019):

• Exploiting In Vivo Precision Pharmacology Techniques to Understand Opioid Receptor Signaling in Specific Circuits, Cell Types, and Subcellular Compartments (Clinical Trial Not Allowed) (R61/R33)
• • • Application due date: 10/17/19
• Systems of Care Special Program Clinical Projects
  • Application due date: 8/5/19

• Availability of funds for Title X Family Planning– Innovations in Family Planning Clinical Service Delivery and Studies to Address Opportunities and Barriers for Linking Family Planning Services and Substance Use Disorder Screening and Treatment
  • Application due date: 6/14/19

• Strategic Research Award
  • Application due date: 6/24/19

• Administrative Supplement for Research on Bioethical Issues (Admin Supp Clinical Trial Optional)
  • Application due date: 5/13/19

• HEAL Initiative: Early Phase Pain Investigation Clinical Network – Specialized Clinical Centers (U24 Clinical Trial Not Allowed)
  • Earliest submission date: 5/3/19
  • Letter of intent due: 30 days prior to the application due date
  • Application due date: 6/3/19

• Addiction Psychiatry Fellowship Program
  • Application due date: none posted

• Extracellular Vesicles and Substance Use Disorders (R01)
  • Application due date: 10/4/19, 11/3/19, 2/2/20, 3/3/20

• Sickle Cell Disease Competitive Grant Research Program
  • Application due date: 5/13/19

• NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)
  • Application due date: 7/22/19, 9/7/19, 7/22/20, 9/7/20, 7/22/21, 9/7/21

• First Responders-Comprehensive Addiction and Recovery Act
  • Application due date: 5/6/19

• TI-19-010 –Rural Opioid Technical Assistance Grants
  • Application due date: 6/7/19

• Community Facilities Technical Assistance and Training Grant
  • Application due date: 6/10/19 (electronic) or 6/17/19 (mailed)

• RFA-DA-19-037 — Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: CNS Data Generation (UM1 Clinical Trial Not Allowed)
  • Letter of intent due date: 30 days prior to the application due date
  • Application due date: 5/8/19

• Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, Analysis, and Scientific Outreach (UM1 Clinical Trial Not Allowed)
  • Letter of intent due date: 30 days prior to the application due date
  • Application due date: 5/8/19

• Provider’s Clinical Support System – Universities Grants
  • Application due date: 6/7/19

• RFA-DA-19-039 — Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)
  • Application due date: 5/24/19

• Health Technology Assessment (HTA) Programme — Needle and Syringe Exchange Schemes and Opiate Substitution Therapy in the UK
  • Application due date: 7/31/19

• AHRQ Health Services Research Project: Partners Enabling Diagnostic Excellence (R01)
  • Application due date: 5/29/19

• Comprehensive Opioid Abuse Training and Technical Assistance (TTA) Program
  • Application due date: 5/28/19

• NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
  • Letter of intent due date: 30 days prior to the application due date
  • Application due date: 7/25/19, 7/25/20

• Extracellular Vesicles and Substance Use Disorders (R21)
  • Letter of intent due date: 30 days prior to the application due date
  • Application due date: 11/3/19, 3/3/20

• Rural Communities Opioid Response Program – Medication-Assisted Treatment Expansion (RCORP-MATE)
  • Application due date: 6/10/19

• HRSA-19-082: Rural Communities Opioid Response Program-Implementation
  • Current closing date for applications: 5/6/19

• HRSA-19-083: Rural Communities Opioid Response Program-Evaluation
  • Current closing date for applications: 5/6/19

• Opioid Workforce Expansion Program (OWEP) – Professionals and Paraprofessionals

  • Posted Date: 03/08/19
  • Application due date: 05/05/19

 

• Distance Learning and Telemedicine Grants–Opioid
  • Posted date: 2/14/19
  • Application due date: 4/15/19
  • Archive date: 5/15/19
• Rural Communities Opioid Response Program-Implementation
  • Posted date: 1/8/19
  • Estimated synopsis date: 4/8/19

• Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)
  • Posted date: 8/2/18
  • Letter of intent due: 30 days prior to the application due date
  • Application due date: 3/7/19, 11/25/19, 3/12/20

• Clinical Grants
  • Deadline to apply: 3/25/19

• Development of Standard Core Clinical Outcomes Assessments (COAs) and Endpoints (UG3/UH3 Clinical Trial Optional)
  • Posted date: 2/19/19
  • Earliest submission date: 3/1/19
  • Letter of intent due: 4/1/19
  • Application due date: 5/31/19

• Mentoring Opportunities for Youth Initiative
  • Posted date: 2/20/19
  • Application due date: 4/22/19

Funding Opportunities (as of Feb 7, 2019) :

NIH TITLE	FOA	Org	Expires	Activity Code
HEAL Initiative: Back Pain Consortium (BACPAC) Research Program: Phase 2 Clinical Trials (UG3/UH3 Clinical Trial Required)	RFA-AR-19-029	NIAMS	Feb 26, 2019	UG3/UH3
HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Methodology and Advanced Analytics Resource Center (U2C Clinical Trial Not Allowed)	RFA-DA-19-023	NIDA	Feb 27, 2019	U2C
HEAL Initiative: Sleep and Circadian-Dependent Mechanisms Contributing to Opiate Use Disorder (OUD) and Response to Medication Assisted Treatment (MAT) (U01 Clinical Trial Optional)	RFA-HL-19-029	NHLBI	Feb 27, 2019	U01
HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Coordination and Translation Center (U2C Clinical Trial Optional)	RFA-DA-19-024	NIDA	Feb 27, 2019	U2C
HEAL Initiative: Sleep and Circadian-Dependent Mechanisms Contributing to Opiate Use Disorder (OUD) and Response to Medication Assisted Treatment (MAT) (R01 – Clinical Trial Not Allowed)	RFA-HL-19-028	NHLBI	Feb 27, 2019	R01
HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Clinical Research Centers (UG1 Clinical Trial Optional)	RFA-DA-19-025	NIDA	Feb 27, 2019	UG1
Promoting Research on Music and Health: Fundamentals and Applications (R21 Clinical Trials Optional)	RFA-NS-19-009	NINDS	Feb 28, 2019	R21
Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33 Clinical Trial Optional)	RFA-AT-19-001	NCCIH	Feb 28, 2019	R61/R33
Promoting Research on Music and Health: Fundamentals and Applications (R01 Clinical Trials Optional)	RFA-NS-19-008	NINDS	Feb 28, 2019	R01
HEAL Initiative: Tissue Chips to Model Nociception, Addiction, and Overdose (UG3/UH3 Clinical Trial Not Allowed)	RFA-TR-19-003	NCATS	Feb 28, 2019	UG3/UH3
HEAL Initiative: Biofabricated 3D Tissue Models of Nociception, Opioid Use Disorder and Overdose for Drug Screening (UH2/UH3 Clinical Trial Not Allowed)	RFA-TR-19-005	NCATS	Feb 28, 2019	UH2/UH3
Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Not Allowed)	RFA-NS-19-010	NINDS	Mar 6, 2019	UG3/UH3
HEAL Initiative: Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain – (U44 Clinical Trial Not Allowed)	RFA-NS-19-020	NINDS	Mar 6, 2019	U44
HEAL Initiative: Coordinating Center to Support NIDA Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) Initiative (U24 Clinical Trial Not Allowed)	RFA-DA-19-034	NIDA	Mar 13, 2019	U24
HEAL Initiative: Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) (UG3/UH3 Clinical Trial Required)	RFA-DA-19-035	NIDA	Mar 13, 2019	UG3/UH3
HEAL Initiative Limited Competition: Behavioral Research to Improve MAT: Ancillary Studies to Enhance Behavioral or Social Interventions to Improve Adherence to Medication Assisted Treatment for Opioid Use Disorders (R01, Clinical Trials Optional)	RFA-AT-19-007	NCCIH	Mar 15, 2019	R01
Heal Initiative: Pragmatic Randomized Controlled Trial of Acupuncture for Management of Chronic Low Back Pain in Older Adults (UG3/UH3 Clinical Trial Required)	RFA-AT-19-005	NCCIH	Mar 15, 2019	UG3/UH3
Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R01 Clinical Trial Optional)	RFA-AT-19-008	NCCIH	Mar 15, 2019	R01
Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R21 Clinical Trial Optional)	RFA-AT-19-009	NCCIH	Mar 15, 2019	R21
HEAL Initiative: Back Pain Consortium (BACPAC) Research Program: Mechanistic Research Centers (U19 Clinical Trial Optional)	RFA-AR-19-026	NIAMS	Mar 20, 2019	U19
HEAL Initiative: Back Pain Consortium (BACPAC) Research Program Data Integration, Algorithm Development and Operations Management Center (U24 Clinical Trial Not Allowed)	RFA-AR-19-027	NIAMS	Mar 20, 2019	U24
HEAL Initiative: Back Pain Consortium (BACPAC) Research Program Technology Research Sites (UH2/UH3 Clinical Trial Optional)	RFA-AR-19-028	NIAMS	Mar 20, 2019	UH2/UH3
Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R41/R42 – Clinical Trial Optional)	RFA-DA-19-032	NIDA	Mar 20, 2019	R41/R42
Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R43/R44 – Clinical Trial Optional)	RFA-DA-19-033	NIDA	Mar 20, 2019	R43/R44
HEAL Initiative: HEALthy Brain and Child Development Study (HEALthy BCD) (Collaborative R34- Clinical Trial Not Allowed)	RFA-DA-19-029	NIDA	Mar 25, 2019	R34
HEAL Initiative: HEALthy Brain and Child Development Study (HEALthy BCD) ( R34- Clinical Trial Not Allowed)	RFA-DA-19-036	NIDA	Mar 25, 2019	R34
HEAL Initiative: Integrated Approach to Pain and Opioid Use in Hemodialysis Patients: The Hemodialysis Opioid Prescription Effort (HOPE) Consortium – Clinical Centers (U01 Clinical Trial Required)	RFA-DK-18-030	NIDDK	Mar 27, 2019	U01
HEAL Initiative: Integrated Approach to Pain and Opioid Use in Hemodialysis Patients: The Hemodialysis Opioid Prescription Effort (HOPE) Consortium – Scientific and Data Research Center (U01 Clinical Trial Required)	RFA-DK-18-031	NIDDK	Mar 27, 2019	U01
HEAL Initiative: Antenatal Opioid Exposure Longitudinal Study Consortium (PL1 Clinical Trials Not Allowed)	RFA-HD-19-025	NICHD	Mar 29, 2019	PL1
Patient Safety Learning Laboratories (2019): Pursuing Safety in Diagnosis and Treatment at the Intersection of Design, Systems Engineering, and Health Services Research (R18)	RFA-HS-19-001	AHRQ	Mar 31, 2019	R18
HEAL Initiative: Effectiveness Trials to Optimize, Implement, Scale, and Sustain the Collaborative Care Model for Individuals with Opioid Use Disorders and Mental Health Conditions (U01 Clinical Trial Required)	RFA-MH-19-525	NIMH	Apr 1, 2019	U01
PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)	PA-18-574	NIH	Apr 5, 2019	R43/R44
PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)	PA-18-575	NIH	Apr 5, 2019	R41/R42
PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)	PA-18-576	NIH	Apr 5, 2019	R41/R42
PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)	PA-18-573	NIH	Apr 5, 2019	R43/R44
Prescription Drug Abuse (R01 Clinical Trial Optional)	PA-18-058	NIDA	May 7, 2019	R01
Prescription Drug Abuse (R21 Clinical Trial Optional)	PA-18-076	NIDA	May 7, 2019	R21
Mechanisms, Models, Measurement, and Management in Pain Research (R01 Clinical Trial Optional)	PA-18-141	NINR	May 7, 2019	R01
Mechanisms, Models, Measurement, and Management in Pain Research (R21 Clinical Trial Optional)	PA-18-159	NINR	May 7, 2019	R21
Womens HIV Epidemiology Cohort Studies (R01 Clinical Trial Not Allowed)	RFA-HD-19-024	NICHD	May 14, 2019	R01
Simulation Modeling and Systems Science to Address Health Disparities (R01-Clinical Trial Not Allowed)	PAR-18-331	NIMHD	Jun 7, 2019	R01
Collaborative Minority Health and Health Disparities Research with Tribal Epidemiology Centers (R01)	PAR-17-484	NIMHD	Dec 4, 2019	R01
Collaborative Minority Health and Health Disparities Research with Tribal Epidemiology Centers (R21)	PAR-17-483	NIMHD	Dec 4, 2019	R21
Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional)	RFA-DA-19-002	NIDA	Jan 1, 2020	UG3/UH3
Safety and Outcome Measures of Pain Medications Used in Children and Pregnant Women (R01 Clinical Trial Optional)	PA-18-038	NICHD	Jan 7, 2020	R01
Safety and Outcome Measures of Pain Medications Used in Children and Pregnant Women (R21 Clinical Trial Optional)	PA-18-043	NICHD	Jan 7, 2020	R21
Safety and Outcome Measures of Pain Medications Used in Children and Pregnant Women (R03 Clinical Trial Optional)	PA-18-044	NICHD	Jan 7, 2020	R03
Neuroscience Research on Drug Abuse (R01 Clinical Trial Optional)	PA-18-060	NIDA	Jan 7, 2020	R01
Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional)	PA-18-078	NIDA	Jan 7, 2020	R21
Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)	PAR-18-662	NCCIH	Feb 28, 2020	UG3/UH3
NCCIH Mind and Body Clinical Trial Cooperative Agreement (U01 Clinical Trial Required)	PAR-18-118	NCCIH	Feb 29, 2020	U01
Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)	RFA-NS-18-041	NINDS	Mar 12, 2020	R61/R33
Analytical and/or Clinical Validation of a Candidate Biomarker for Pain (R61/R33 Clinical Trial Optional)	RFA-NS-18-046	NINDS	Mar 12, 2020	R61/R33
Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R21)	PA-17-157	NIDA	May 7, 2020	R21
Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R01)	PA-17-155	NIDA	May 7, 2020	R01
Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R01 Clinical Trial Optional)	PA-18-061	NIDA	May 7, 2020	R01
Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R21 Clinical Trial Optional)	PA-18-079	NIDA	May 7, 2020	R21
Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R03 Clinical Trial Optional)	PA-18-080	NIDA	May 7, 2020	R03
Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (R61/R33 Clinical Trial Optional)	RFA-DA-19-003	NIDA	Jul 17, 2020	R61/R33
Assay development and screening for discovery of chemical probes or therapeutic agents (R01)	PAR-17-438	NCI	Sep 7, 2020	R01
Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 – Clinical Trials Required)	PAR-18-417	NCCIH	Sep 7, 2020	R34
Mechanistic investigations of psychosocial stress effects on opioid use patterns (R01- Clinical Trial Optional)	PAS-18-624	NIDA	Sep 7, 2020	R01
Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21- Clinical Trial Optional)	PAS-18-625	NIDA	Sep 7, 2020	R21
Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R21 Clinical Trial Optional)	PAR-18-745	NIMHD	Nov 13, 2020	R21
Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R01 Clinical Trial Optional)	PAR-18-747	NIMHD	Nov 13, 2020	R01
NINDS Exploratory Clinical Trials for Small Business (R44) – Clinical Trial Required	PAR-18-618	NINDS	Jan 5, 2021	R44
NINDS Exploratory Clinical Trials for Small Business (R42) – Clinical Trial Required	PAR-18-617	NINDS	Jan 5, 2021	R42
Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional)	PA-18-775	NIDA	Jan 7, 2021	R34
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp – Clinical Trial Optional)	PA-18-591	NIH	Jan 25, 2021	(Admin Supp)
Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 Clinical Trial Optional)	PAR-18-742	NIDA	Feb 11, 2021	R61/R33
HEAL Initiative: Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)	RFA-NS-19-016	NINDS	Feb 22, 2021	UG3/UH3
HEAL Initiative: Translational Devices to Treat Pain (U44 Clinical Trial Optional)	RFA-NS-19-017	NINDS	Feb 22, 2021	U44
HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional)	RFA-NS-19-018	NINDS	Feb 22, 2021	UH3
HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)	RFA-EB-18-003	NIBIB	Feb 22, 2021	U18
Drug Repurposing for Conditions Affecting Neonates and Pregnant Women (R01 – Clinical Trial Optional)	PAR-18-506	NICHD	May 7, 2021	R01
Genetics of Alcohol Sensitivity and Tolerance (R01 Clinical Trial Not Allowed)	PA-18-660	NIAAA	May 7, 2021	R01
Developmental Pharmacodynamics and Models of Drug Effects in Pediatrics (R03 Clinical Trial Optional)	PA-18-687	NICHD	May 7, 2021	R03
Developmental Pharmacodynamics and Models of Drug Effects in Pediatrics (R01 Clinical Trial Optional)	PA-18-688	NICHD	May 7, 2021	R01
International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional)	PA-18-773	NIDA	May 7, 2021	R01
Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34 – Clinical Trial Optional)	PA-18-780	NIDA	May 7, 2021	R34
HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)	PAS-18-915	NIDA	Sep 7, 2021	R01
Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 – Clinical Trial Optional)	PA-18-917	NIDA	Sep 7, 2021	R01
HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R43/R44 – Clinical Trial Optional)	RFA-DA-19-019	NIDA	Sep 8, 2021	R43/R44
HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R41/R42 – Clinical Trial Optional)	RFA-DA-19-020	NIDA	Sep 8, 2021	R41/R42
Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed)	PAR-19-039	NINDS	Sep 14, 2021	U01
Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)	PAR-19-040	NINDS	Sep 14, 2021	U01
Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)	PAR-19-064	NIDA	Nov 8, 2021	R21
Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)	PAR-19-100	NCATS	Nov 9, 2021	R21
Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award, (U01 Clinical Trial Optional)	PAR-19-099	NCATS	Nov 9, 2021	U01
Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)	PA-18-932	ODP	Jan 7, 2022	R01
Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R21 Clinical Trial Optional)	PA-18-946	NINR	Jan 7, 2022	R21
Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional)	PA-18-945	NINR	Jan 7, 2022	R01
Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)	PA-18-943	NINR	Jan 7, 2022	R21
Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)	PA-18-944	NINR	Jan 7, 2022	R01
End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional)	PAR-19-045	NINR	Jan 7, 2022	R01
End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21- Clinical Trial Optional)	PAR-19-044	NINR	Jan 7, 2022	R21

 

UMKC Health Sciences District Research Council members

Dr. Jinwen Cai, Kansas City, Missouri Health Department

Dr. Kathy Goggin, Children’s Mercy Hospital

Dr. Mark Hecker, UMKC School of Medicine

Dr. Jessica Hellings, Truman Medical Centers Behavioral Health

Dr. Jianwei Jiao, Center for Behavioral Medicine

Dr. Joseph Lightner, UMKC School of Nursing and Health Studies

Dr. Russell Melchert, UMKC School of Pharmacy

Dr. Paula Monaghan-Nichols, UMKC School of Medicine

Dr. Mark Nichols, UMKC School of Medicine

Dr. Mark Steele, Truman Medical Centers

Dr. Mary Walker, UMKC School of Dentistry